Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive…

By E. Lawitz, M. Sulkowski, R. Ghalib, M. Rodríguez-Torres, Z. Younossi, A. Corregidor, E. Dejesus, Brian L. Pearlman, M. Rabinovitz, N. Gitlin and 12 more. The Lancet, 2014

844 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/c83ecd36b0da8f16c9162dabcaa743343a90480b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. G. Dusheiko
2. J. Pawlotsky
3. M. Puoti
4. A. Aghemo
5. X. Forns
6. Christoph Sarrazin
7. Aasld Idsa Hcv Guidance Panel

In Hepatology

1. J. Pawlotsky
2. G. Dusheiko
3. M. Puoti
4. A. Aghemo
5. X. Forns
6. Christoph Sarrazin
7. Aasld Idsa Hcv Guidance Panel

Citations in the corpus

• Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (2015, background): “Similarly, patients with cirrhosis who are being treated with simeprevir plus sofosbuvir should receive 24 weeks of therapy.(92,93) Genotype 1b.”
• Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection (2017, methodology): “We identified 3 studies using this regimen (14, 28, 46).”
• EASL Recommendations on Treatment of Hepatitis C 2015. (2015, methodology): “All virological failures were due to post-treatment relapses [11].”